CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleLevered free cash flow is $1.26B, higher than 95% of all stocks globally
- PositionOperating margin is 29.6%, higher than 95% of its Diagnostics & Research peers (median 5%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.67%
Annual Rate
USD 0.01Paid unknown
Payout Ratio
32.7%Sustainable
Last Ex-Dividend
May 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
296.48MUSDvs all stocks (USD)
Revenue (TTM)
7.86BEGPvs all stocks (USD)
Profit Margin
17.42%vs Diagnostics & Research peers
Beta
0.3960xvs all stocks
52-Week Change
48.26%vs all stocks
Forward Annual Dividend Yield
1.67%vs all stocks
Market Capitalization
296.48MUSDvs all stocks (USD)
Enterprise Value
238.91MUSDvs all stocks (USD)
Forward P/E
0.2881xvs Diagnostics & Research peers
PEG Ratio
0.0001xPrice to Sales (TTM)
0.0377xvs Diagnostics & Research peers
Price to Book (MRQ)
0.0949xvs Diagnostics & Research peers
Enterprise to Revenue
0.0304xvs Diagnostics & Research peers
Enterprise to EBITDA
0.0822xvs Diagnostics & Research peers
Gross Margin
38.93%vs Diagnostics & Research peers
Profit Margin
17.42%vs Diagnostics & Research peers
Operating Margin
29.62%vs Diagnostics & Research peers
Return on Assets (TTM)
14.69%vs Diagnostics & Research peers
Return on Equity (TTM)
30.56%vs Diagnostics & Research peers
Revenue (TTM)
7.86BEGPvs all stocks (USD)
Revenue per Share (TTM)
13.51EGPUpdated Jul 19, 2026Quarterly Revenue Growth
31.00%vs Diagnostics & Research peers
Gross Profit (TTM)
3.35BEGPvs all stocks (USD)
EBITDA (TTM)
1.19BEGPvs all stocks (USD)
Net Income (TTM)
1.26BEGPvs all stocks (USD)
Quarterly Earnings Growth (YoY)
78.40%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
1.53BEGPvs all stocks (USD)
Levered Free Cash Flow (TTM)
1.26BEGPvs all stocks (USD)
Forward Annual Dividend Rate
0.0100USDUpdated Jul 19, 2026Forward Annual Dividend Yield
1.67%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
32.68%vs Diagnostics & Research peers
Minority Interest (Equity)
747.26MEGPFY2025 · Dec 31, 2025Revenue
7.86BEGPFY2025 · Dec 31, 2025Cost of Goods Sold
4.50BEGPFY2025 · Dec 31, 2025Gross Profit
3.35BEGPFY2025 · Dec 31, 2025Operating Income
2.12BEGP42.24M · vs all stocks (USD)
Pre-tax Income
2.12BEGPFY2025 · Dec 31, 2025Income Tax Expense
816.89MEGPFY2025 · Dec 31, 2025Net Income
1.30BEGPFY2025 · Dec 31, 2025EBIT
2.33BEGPFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.91BEGPFY2025 · Dec 31, 2025Selling, General & Administrative
632.84MEGPFY2025 · Dec 31, 2025Other Operating Expenses
1.93MEGPFY2025 · Dec 31, 2025Non-operating Interest Income
222.91MEGPFY2025 · Dec 31, 2025Non-operating Interest Expense
208.50MEGPFY2025 · Dec 31, 2025EPS (Basic)
2.17EGPFY2025 · Dec 31, 2025EPS (Diluted)
2.17EGPFY2025 · Dec 31, 2025Basic Shares Outstanding
581.33MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
581.33MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-39.46MEGPFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EGPFY2025 · Dec 31, 2025Operating Cash Flow
1.53BEGPFY2025 · Dec 31, 2025Free Cash Flow
1.11BEGPFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.67BEGPFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.12BEGPFY2025 · Dec 31, 2025Stock-based Compensation
-1.38MEGPFY2025 · Dec 31, 2025Other Non-cash Items
-28.39MEGPFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-446.25MEGPFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-110.56MEGPFY2025 · Dec 31, 2025Capital Expenditures
-425.85MEGPFY2025 · Dec 31, 2025Net Intangibles (CF)
-84.89MEGPFY2025 · Dec 31, 2025Net Acquisitions
-340.00MEGPFY2025 · Dec 31, 2025Purchase of Investments
-882.53MEGPFY2025 · Dec 31, 2025Sale of Investments
965.00MEGPFY2025 · Dec 31, 2025Net Investing Cash Flow
-683.38MEGPFY2025 · Dec 31, 2025Long-term Debt Issuance
383.46MEGPFY2025 · Dec 31, 2025Long-term Debt Payments
-219.82MEGPFY2025 · Dec 31, 2025Common Stock Repurchase
0.00EGPFY2025 · Dec 31, 2025Common Dividends Paid
-535.14MEGPFY2025 · Dec 31, 2025Other Financing Charges
23.81MEGPFY2025 · Dec 31, 2025Net Financing Cash Flow
-347.69MEGPFY2025 · Dec 31, 2025Shares Outstanding
581.33MSharesUpdated Jul 19, 2026Float Shares
39.83MSharesUpdated Jul 19, 2026% Held by Insiders
62.00%vs all stocks
% Held by Institutions
41.33%vs all stocks
Total Cash (MRQ)
675.85MEGPvs all stocks (USD)
Total Cash per Share (MRQ)
1.16EGPUpdated Jul 19, 2026Total Debt (MRQ)
1.27BEGPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3906xvs Diagnostics & Research peers
Current Ratio (MRQ)
1.59xvs Diagnostics & Research peers
Book Value per Share (MRQ)
5.37EGPUpdated Jul 19, 2026Total Assets
8.60BEGP170.91M · vs all stocks (USD)
Total Current Assets
3.95BEGPFY2025 · Dec 31, 2025Total Liabilities
4.46BEGPFY2025 · Dec 31, 2025Total Non-current Assets
4.64BEGPFY2025 · Dec 31, 2025Total Non-current Liabilities
1.77BEGPFY2025 · Dec 31, 2025Total Current Liabilities
2.70BEGPFY2025 · Dec 31, 2025Cash
363.26MEGPFY2025 · Dec 31, 2025Cash Equivalents
1.31BEGPFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.67BEGPFY2025 · Dec 31, 2025Other Short-term Investments
454.29MEGPFY2025 · Dec 31, 2025Accounts Receivable
996.49MEGPFY2025 · Dec 31, 2025Inventory
424.43MEGPFY2025 · Dec 31, 2025Accounts Payable
563.45MEGPFY2025 · Dec 31, 2025Short-term Debt
418.71MEGPFY2025 · Dec 31, 2025Long-term Debt
1.19BEGPFY2025 · Dec 31, 2025Common Stock (Book)
1.04BEGPFY2025 · Dec 31, 2025Retained Earnings
2.60BEGPFY2025 · Dec 31, 2025Total Shareholders' Equity
4.13BEGP82.13M · vs all stocks (USD)
52-Week Low
0.3290USDUpdated Jul 19, 202652-Week High
0.8350USDUpdated Jul 19, 202652-Week Change
48.26%vs all stocks
Beta
0.3960xvs all stocks
50-Day MA
0.5481USDUpdated Jul 19, 2026200-Day MA
0.6032USDUpdated Jul 19, 2026Avg 10-Day Volume
199.74KSharesUpdated Jul 19, 2026Avg 30-Day Volume
319.72KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.0500EGPUpdated Jul 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 29.6%, higher than 95% of its Diagnostics & Research peers (median 5%)Significant
Operating margin: 0.30Industry median: 0.05Industry P95: 0.27Peers compared: 31.00
Return on equity is 30.6%, higher than 95% of its Diagnostics & Research peers (median 1.1%)Significant
Return on equity: 0.31Industry median: 0.01Industry P95: 0.30Peers compared: 31.00
Price-to-book is 0.09×, lower than 95% of its Diagnostics & Research peers (median 2.05×)Notable
Price-to-book: 0.09Industry median: 2.05Industry P5: 0.52Peers compared: 31.00
Financial Health
Altman Z-Score 4.43: safe zoneNotable
Altman Z-Score: 4.43
High earnings qualityNotable
Earnings Quality Score: 1.00
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Levered free cash flow is $1.26B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 1,262,207,000Global P95: 1,123,592,359.78
Revenue is $7.86B, above the global median of $520.53MNotable
Revenue (USD): 7,855,407,000Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Huaiji Dengyun Auto Parts Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Haxc Holdings Beijing Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlow
Shanghai Huaming Intelligent Terminal Equipment Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Nak Sealing Technologies Corp.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Komatsu Wall Industry Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Jalco Holdings Inc.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Zhejiang Renzhi Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Zhejiang Benli Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Japan Eyewear Holdings Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRule
Mangalam Cement Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sectra AB
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
IMI plc
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin